ANGPT2 and newborn respiratory distress syndrome: On the basis of the increased levels of Ang2 in respiratory distress syndrome, an investigational anti-Ang2 monoclonal antibody (LY3127804) for COVID-19 is now in a Phase 2 clinical trial.